Golidocitinib
A Janus kinase inhibitor used in cancer treatment
| Golidocitinib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Golidocitinib is a Janus kinase (JAK) inhibitor that is being investigated for its potential use in the treatment of various cancers. It specifically targets the JAK1 enzyme, which plays a crucial role in the signaling pathways that regulate immune function and cell growth.
Mechanism of Action[edit]
Golidocitinib functions by selectively inhibiting the activity of the JAK1 enzyme. The JAK family of enzymes, which includes JAK1, JAK2, JAK3, and TYK2, is involved in the signaling pathways of various cytokine receptors. By inhibiting JAK1, golidocitinib disrupts the JAK-STAT signaling pathway, which is often dysregulated in cancer cells, leading to uncontrolled cell proliferation and survival.
Clinical Development[edit]
Golidocitinib is currently undergoing clinical trials to evaluate its efficacy and safety in treating different types of cancers, including lymphoma and solid tumors. The drug is being studied both as a monotherapy and in combination with other anticancer agents.
Pharmacokinetics[edit]
The pharmacokinetic profile of golidocitinib includes its absorption, distribution, metabolism, and excretion characteristics. It is designed to be orally bioavailable, allowing for convenient administration. The drug is metabolized primarily in the liver and excreted through both renal and fecal pathways.
Potential Side Effects[edit]
As with other JAK inhibitors, golidocitinib may cause side effects related to its immunosuppressive action. Common adverse effects observed in clinical trials include neutropenia, anemia, and increased risk of infections. Monitoring of blood counts and liver function tests is recommended during treatment.
Research and Development[edit]
Research on golidocitinib is focused on understanding its full therapeutic potential and optimizing its use in combination therapies. Ongoing studies aim to identify biomarkers that predict response to treatment and to explore its effects on the tumor microenvironment.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
